---
title: >-
  Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed,
  Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice.
description: >-
  Explore this publication on real-world evidence: Effectiveness and Safety of
  Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic
  Immune…
date: '2021-01-01'
category: Publications
tags:
  - Advances In Therapy
  - Abstract / Manuscript
  - R&D
  - Care
  - Methods/Pharmacoepi
  - Hematology
  - Pharma Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/advances-in-therapy/effectiveness-and-safety-of-romiplostim-among-patients-with/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: effectiveness-and-safety-of-romiplostim-among-patients-with
id: YfaIw4gzbXfZ7ScaLQRMn
contentType: article
---

## Challenge

Romiplostim had demonstrated efficacy in clinical trials for immune thrombocytopenia, but real-world effectiveness and safety data across the full spectrum of ITP disease phases in US hematology practice were lacking.

## Solution

Target RWE researchers analyzed real-world data to characterize the effectiveness and safety of romiplostim across ITP disease phases in US hematology clinics, documenting response rates, adverse events, and treatment duration patterns.

## Impact

Establishing romiplostim's real-world effectiveness and safety profile across ITP phases provides Amgen with post-authorization evidence supporting label communications and formulary positioning.